Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • ejp.1180

    Final published version, 355 KB, PDF document


  • P Hansson, Department of Pain Research & Treatment, Division of Emergencies and Critical Care, Oslo University Hospital, Norway.
  • ,
  • Troels Staehelin Jensen
  • G Kvarstein, Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
  • ,
  • M Strömberg, Astellas Pharma A/S Nordic Operations, Kastrup, Denmark.

CONTEXT: Clinical trials have demonstrated the efficacy and safety of the capsaicin 8% patch in patients with peripheral neuropathic pain (PNP); however, few studies have assessed this treatment in a clinical practice.

OBJECTIVE: To determine whether treatment and re-treatment with the capsaicin 8% patch reduce PNP intensity in clinical practice.

METHODS: Three non-interventional, observational studies were concurrently conducted in Denmark, Norway and Sweden. Patients with probable or definite PNP received one or two treatments with the capsaicin 8% patch according to usual clinical practice. All analyses were performed on combined data.

RESULTS: Overall, 382 and 181 patients received treatment and re-treatment, respectively, with the capsaicin 8% patch. At the group level, a significant reduction in mean level of 'usual pain' intensity (Numerical Pain Rating Scale) over the last 24 h' score was observed from baseline to Weeks 2 through 8 [-1.05 (95% confidence interval: -1.27, 0.82); p < 0.001] with 28% and 31% of patients reporting a ≥30% reduction in pain after first treatment and re-treatment, respectively. Improvements in health-related quality of life (EQ-5D-3L index) and overall health status (Patient Global Impression of Change) were observed early (Week 1) and throughout the treatment periods. Most application site reactions subsided within a week after treatment. Following treatment and re-treatment, 57% and 71% of patients, respectively, were willing to undergo further treatment with the capsaicin 8% patch.

CONCLUSION: In Scandinavian clinical practice, capsaicin 8% patch treatment was associated with significant reductions in pain intensity and was well tolerated with over half of patients willing to undergo re-treatment.

Original languageEnglish
JournalEuropean journal of pain (London, England)
Pages (from-to)941-950
Publication statusPublished - May 2018

    Research areas

  • Journal Article

See relations at Aarhus University Citationformats

Download statistics

No data available

ID: 121143807